Panacea Life Sciences Holdings, Inc. (PLSH) Income Statement Analysis

See more : Killbuck Bancshares, Inc. (KLIB) Income Statement Analysis – Financial Results

Complete financial analysis of Panacea Life Sciences Holdings, Inc. (PLSH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Panacea Life Sciences Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Ways Electron Co.,Ltd. (605218.SS) Income Statement Analysis – Financial Results
The Tinplate Company of India Limited (TINPLATE.BO) Income Statement Analysis – Financial Results
Hangzhou Oxygen Plant Group Co.,Ltd. (002430.SZ) Income Statement Analysis – Financial Results
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (600671.SS) Income Statement Analysis – Financial Results
Imperial Resources, Inc. (IPRC) Income Statement Analysis – Financial Results

Panacea Life Sciences Holdings, Inc. (PLSH)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.panacealife.com

About Panacea Life Sciences Holdings, Inc.

Panacea Life Sciences Holdings, Inc., a seed to sale cannabinoid and nutraceutical manufacturer and research company, develops and produces natural pharmaceutical alternatives for consumers and pets. The company manufactures and sells softgels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals. It is also involved in the personal protection equipment (PPE) business, including importing and selling PPE hand sanitizers and masks, as well as white label and contract manufacturing sales to other cannabinoid companies, raw material sales, and tolling arrangements. The company was incorporated in 2008 and is headquartered in Greenwood Village, Colorado.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	2.38M	1.63M	2.06M	9.02M	345.68K	0.00	0.00	0.00	213.00
Cost of Revenue	6.47M	1.23M	1.52M	7.02M	2.05M	0.00	0.00	0.00	20.63K
Gross Profit	-4.09M	396.47K	540.58K	2.00M	-1.70M	0.00	0.00	0.00	-20.41K
Gross Profit Ratio	-171.48%	24.37%	26.25%	22.15%	-491.92%	0.00%	0.00%	0.00%	-9,583.10%
Research & Development	0.00	0.00	0.00	0.00	22.10K	300.00K	356.08K	369.34K	77.34K
General & Administrative	1.44M	1.09M	1.52M	2.81M	731.26K	0.00	0.00	0.00	0.00
Selling & Marketing	17.95K	209.25K	377.92K	638.63K	254.87K	0.00	0.00	0.00	0.00
SG&A	1.46M	1.09M	1.52M	2.81M	8.95M	2.14M	1.64M	1.23M	289.69K
Other Expenses	0.00	4.70M	4.56M	4.45M	4.12M	2.14M	2.77M	1.23M	291.31K
Operating Expenses	2.37M	5.79M	6.08M	7.26M	8.97M	2.44M	2.00M	1.60M	367.03K
Cost & Expenses	7.93M	7.03M	7.60M	14.28M	11.02M	2.44M	2.00M	1.60M	368.66K
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	683.24K	2.05M	1.11M	1.51M	479.11K	-464.47K	-68.57K	0.00	0.00
Depreciation & Amortization	1.71M	1.73M	1.74M	1.69M	892.30K	405.17K	52.80K	22.82K	1.63K
EBITDA	-4.75M	-5.36M	-1.94M	-2.03M	-8.65M	-3.48M	-3.12M	-1.60M	-356.35K
EBITDA Ratio	-199.02%	-209.44%	-210.66%	-51.69%	-2,829.33%	0.00%	0.00%	0.00%	-172,211.27%
Operating Income	-5.55M	-5.40M	-5.54M	-5.26M	-10.67M	-2.44M	-2.00M	-1.60M	-368.44K
Operating Income Ratio	-232.55%	-331.81%	-269.00%	-58.31%	-3,087.46%	0.00%	0.00%	0.00%	-172,976.53%
Total Other Income/Expenses	-2.47M	-3.49M	1.15M	26.01K	653.94K	-1.90M	-1.86M	-5.53K	10.46K
Income Before Tax	-8.02M	-9.14M	-4.78M	-5.23M	-10.02M	-4.34M	-3.86M	-1.60M	-357.98K
Income Before Tax Ratio	-336.08%	-561.94%	-232.20%	-58.02%	-2,898.29%	0.00%	0.00%	0.00%	-168,064.32%
Income Tax Expense	0.00	1.96M	1.34M	1.76M	-537.47K	-161.14K	-52.52K	-22.82K	3.00
Net Income	-8.02M	-11.10M	-6.12M	-6.99M	-9.48M	-4.34M	-3.86M	-1.60M	-357.98K
Net Income Ratio	-336.08%	-682.14%	-297.35%	-77.57%	-2,742.81%	0.00%	0.00%	0.00%	-168,064.32%
EPS	-0.48	-0.75	-0.34	-0.41	-7.83	-25.49	-25.47	-18.68	-156.61
EPS Diluted	-0.48	-0.75	-0.34	-0.41	-7.83	-25.49	-25.47	-18.68	-156.61
Weighted Avg Shares Out	16.63M	14.86M	17.82M	16.92M	1.21M	170.14K	151.55K	85.81K	2.29K
Weighted Avg Shares Out (Dil)	16.63M	14.86M	17.82M	16.92M	1.21M	170.14K	151.55K	85.81K	2.29K

Executives Buy Over $1.5M Of 4 Penny Stocks

April 7, 2022benzinga.com

US crude oil futures traded lower on Thursday. Investors, meanwhile, focused on some notable insider trades.

Panacea Life Sciences Ready To Launch CBD And CBG Products In Brazil

February 3, 2022benzinga.com

Panacea Life Sciences, Inc. PLSH announced launch of its CBD and CBG line of products to MyPharma2Go's healthcare providers in Brazil. The new partnership, signed last month, allows Panacea to offer their premium cannabinoid products to the Brazilian market and...

Panacea Life Sciences, Inc. Announces Exclusive Partnership with Amazon Platform Partner Bright Ideas Unlimited, LLC

January 24, 2022accesswire.com

GOLDEN, CO / ACCESSWIRE / January 24, 2022 / Panacea Life Sciences, Inc. (OTCQB:PLSH), (the "Company"), a cGMP certified, vertically integrated, premium cannabinoid company, today announced their exclusive agreement with Bright Ideas Unlimited, LLC (BIU), an Amazon.com, Inc. platform partner,...